Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: Terrapin who wrote (6414)	3/23/1999 1:12:00 PM
From: TwoBear	Read Replies (2) \| Respond to of 78516

John, I thought I would give you another informed opinion on the subject of prostate seed implants. While the facilities that are performing these procedures may be strong advocates, what they want tell you about are the reimbursement rates from Medicare. The healthcare organization that I work for analyzed the procedure and came to the conclusion that it is a money loser. The procedure is very labor and cost intensive. So, we left it to the major academic centers to handle. Many other facilities I speak with are coming to the same conclusions. Also, HCFA is currently setting reimbursement for the new APC (Ambulatory Payment Classifications)as part of the Hospital Outpatient Prospective Payment System. I have seen the proposed reimbursement numbers and they are atrocious, especially for brachytherapy. Following is a quote form Larry Kun, chairman of the board of directors for ASTRO (American Society of Therapeutic Radiology and Oncology), to Nancy DeParle at HCFA, "the proposed changes will definitely curtail and may totally eliminate access to all but the most rudimentary brachytherapy treatments." Just some more information to keep you informed. 2